上海医药：二羟丙茶碱注射液获得批准生产

Group 1 - The core point of the article is that Shanghai Pharmaceutical's subsidiary, Shanghai Hefeng Pharmaceutical Co., Ltd., has received a drug registration certificate from the National Medical Products Administration for its Dihydroxypropyl Theophylline Injection, which is approved for production [2]. Group 2 - The Dihydroxypropyl Theophylline Injection is indicated for the relief of symptoms in bronchial asthma, asthmatic bronchitis, and obstructive pulmonary emphysema, and can also be used for asthma caused by cardiogenic pulmonary edema [1].